登入 加入會員 求助
 
Changchun Changsheng Life Sciences Ltd.
 
 
Recommended Results 
 
Medical Inactivated Influenza Vaccine 

  產品分類 : 化學->化學用品->aspalthic products

     
Medical Inactivated Influenza Vaccine
       

  產品規格
 
Model No:    0.5ml/syringe
  Country  CN
  Minimum Order  5000
  Payment Term  L/C,T/T

 

  產品描述
   
  <p class="MsoNormal">
[Administration and dosage]<br />
(1) Inject i. m. in the deltoid muscle of the lateral upper arm.<br />
(2) Inoculate before and during the epidemic season of influenza. Inject single human dose of 0.5 ml vaccine for adults and children aged above 3 years. Inject two human doses of 0.25 ml vaccine for children aged between 6 months and 3 years at intervals of 2-4 weeks.<br />
[Adverse reactions]<br />
Common adverse reactions<br />
(1) Pain, tenderness, redness, swelling and itching may occur at the injection sites generally within 24 hours after vaccination, which can be relieved spontaneously within 2-3 days in most cases. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />
(2) Transient fever may occur a and can be relieved spontaneously within a short period and need no particular treatment in most cases.<br />
Rare adverse reactions<br />
(1) Transient common cold symptoms and discomfort may occur after vaccination which can be relieved spontaneously and need no particular treatment. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />
(2) Severe fever: Physical therapy and symptomatic treatment shall be adopted to prevent febrile convulsion.<br />
Extremely rare adverse reactions<br />
(1) Allergic rash: Urticaria may occur generally within 72 hours after vaccination, if it occurs the recipients shall go to the clinic promptly and receive anti-anaphylactic treatment.<br />
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination, emergency measures shall be adopted immediately including prompt injection of adrenaline.<br />
(3) Allergic purpura: The recipients with allergic purpura shall go to t.he clinic promptly and receive anti-anaphylactic treatment with corticosteroid. If the treatment is inappropriate or delayed, &nbsp;purpuric &nbsp;nephritis may be complicated.<br />
[Contraindications]<br />
(l) Subjects with known allergic reaction to some components of the vaccine, including subsidiary<br />
materials, formaldehyde, chemicals used for virus desruption and antibiotics.<br />
(2) Subjects with acute diseases, severe chronic diseases, and chronic diseases at acute attack stage<br />
or fever.<br />
(3) Pregnant women.<br />
(4) Subjects with uncontrolled epilepsy, other progressive diseases of nervous system or a history of Guillain-Barre syndrome;
</p>
<span>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Eligibles<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Function and use<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Description<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. )
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Subsidiary materials: All the components of subsidiary materials approved shall be listed.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Specifications<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
0. 25 ml or 0.5 ml per container. &nbsp;0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.
</p>
<img src="http://i.bosscdn.com/product/1d/85/e4/25b2580c5f2d983e504dc14c7e.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Infuenza Vaccine-PFS" alt="Infuenza Vaccine-PFS" /><br />
</span>ccls-vaccine.com

  其他類似產品
 
Rabies vaccine after bite

Rabies vaccine after bite
Medical bulk of Rabies Vaccine

Medical bulk of Rabies Vaccine
Vaccinate Rabies Vaccine For Human

Vaccinate Rabies Vaccine For Human
Lyophilized Meningococcal Polysaccharide Vaccine

Lyophilized Meningococcal Polysaccharide Vaccine
 
   


[ Back Products Catalog ]

Commerce 會員:
請登入您的 帳號 跟 密碼, 系統將自動為您填入您的相關基本資料!
 
帳號:
密碼:
記住我的帳號
 
 
填寫下列表格並寄送詢問函.所有的詢問信函將會自動寄發給你想聯絡的公司
主旨
內容 ﹙ 請勿輸入公司名稱、Email、電話、傳真、網址 ﹚
   

 


公司簡介:

*公司名稱
*E-mail
*國家
*聯絡人
網址
*電話
- -
傳真
- -
*郵遞區號
*城市
*街道地址
*企業形態
批發商   出口商 進口商 製造商
大盤商 零售商  代理商 Retrofitter 使用者
其他, 請詳細說明:
*安全密碼
請輸入所顯示的安全密碼


網站導覽 l 隱私權政策 l 服務團隊 l 合作提案 l 聯絡我們 l 幫幫我 l 廣告刊登 l  B2B商業夥伴
    .